Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a diversified healthcare company headquartered in San Diego, California, specializing in developing innovative medical technologies for point-of-care testing (POCT), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's flagship product is VELDONA®, a low-dose oral interferon-alpha formulation aimed at enhancing immune responses against a range of diseases. Ainos' VELDONA® has shown promise in treating human disease indications such as influenza, hepatitis C, thrombocytopenia, as well as HIV-related oral warts and Behçet's disease, both of which have received Orphan Drug Designation by the U.S. FDA.
Ainos recently announced the completion of manufacturing a GMP Clinical Batch of VELDONA® in collaboration with its contract manufacturer, Swiss Pharmaceutical Co., Ltd. (Taiwan). This milestone validates Ainos' capabilities in delivering high-quality, cost-effective therapeutics and advances the company's key programs.
In addition to human therapeutics, Ainos is making strides in animal health. The company has initiated clinical trials for a new VELDONA®-based drug aimed at treating feline chronic gingivostomatitis, a serious and chronic painful oral disease. This study builds upon VELDONA®'s extensive history in animal health, demonstrating its therapeutic potential across various animal species.
Ainos is also pioneering AI-powered POCTs through its AI Nose technology platform. The company's lead POCT candidate, Ainos Flora, is designed to be a telehealth-friendly solution for women's health and common sexually transmitted infections (STIs). Furthermore, Ainos has initiated a co-development program with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to create a volatile organic compound (VOC) sensing platform. This technology aims to revolutionize applications in telehealth, automotive, industrial, and environmental safety, expanding Ainos' market reach.
Financially, Ainos has secured significant growth capital, including a $9 million convertible note from an existing shareholder. This funding will propel the company's initiatives in scaling up VELDONA® and advancing its AI Nose technology.
With nearly four decades of dedication to healthcare innovation, Ainos continues to push the boundaries of medical science, striving to deliver effective, safe, and high-quality treatments for both humans and animals. Investors and stakeholders are encouraged to follow Ainos on social media platforms like X (formerly Twitter) and LinkedIn for the latest updates and developments.
Ainos (NASDAQ:AIMD) has secured a significant Japanese patent (No. 7619659) for VELDONA®, its innovative oral interferon formulation designed to treat and prevent coronavirus infections. This follows a recent patent approval in Taiwan, strengthening the company's global IP portfolio in a market projected to exceed $16 billion by 2031.
The patent includes 15 key claims covering VELDONA's formulation, featuring low-dose administration under 1,000 IU, sublingual and buccal delivery mechanisms, and flexible dosage forms. Unlike traditional interferon therapies, VELDONA® doesn't require cold chain logistics, significantly reducing costs.
The technology offers dual benefits for coronavirus treatment and prevention, with proven broad-spectrum antiviral efficacy against multiple variants. VELDONA® addresses accessibility through non-invasive oral therapy, affordability by eliminating cold chain dependency, and enhanced safety through its low-dose formulation.
Ainos (NASDAQ:AIMD) received a Water Tower Research report highlighting its AI Nose technology developments and strategic milestones. The report focuses on four key areas: robotics integration, where Ainos seeks partnerships to enhance robot functionality with olfactory capabilities; smart manufacturing, achieving 80% accuracy in identifying 22 VOCs across 761 semiconductor factory samples, with mass production planned for 1H2025; elderly care monitoring in Japan, developing an AI-driven telehealth system for long-term care facilities; and women's health testing through Ainos Flora device, which showed 94% accuracy in detecting vaginal infections and STIs.
The report also covers VELDONA® clinical trials, scheduled to begin in 1H25 for Sjogren's syndrome and HIV-related oral warts in Taiwan, with completion expected in 2026. Animal health trials for FCGS are set to complete in 1H25, with U.S. IND applications planned for 2H25.
Ainos (NASDAQ:AIMD) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company was initially notified on July 15, 2024, that its stock price had been trading below the required $1.00 minimum for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). After the initial 180-day compliance period ending January 13, 2025, Nasdaq has granted Ainos an additional extension until July 14, 2025 to meet the minimum bid requirement.
The company's shares will continue to trade on the Nasdaq Capital Market during this extension period, with no immediate effect on its listing status.
Ainos (NASDAQ:AIMD) has announced its AI Nose technology for robotics applications and launched the Ainos Alliance initiative, inviting global robotics companies to collaborate. The AI Nose technology, developed over nearly a decade, combines AI and MEMS gas sensors to enable robots to detect smells, targeting applications in home safety, healthcare, and industrial environments.
The technology offers capabilities including gas leak detection, disease detection through VOC analysis, and environmental monitoring. This announcement comes amid significant market growth projections, with the global robotics market expected to reach $178.63 billion by 2030, and the electronic nose market projected to hit $65.79 billion by 2031.
Through the Ainos Alliance, robotics companies can access this patented technology to enhance their products' capabilities in industrial safety, healthcare, and smart living applications.
Ainos (NASDAQ:AIMD) has shared its achievements and future plans in a shareholder letter. The company is developing AI Nose technology through Smell ID, achieving 80% accuracy in VOC detection platform with plans for mass production in H1 2025. Their Ainos Flora device for women's health achieved up to 94% accuracy in clinical trials, with second-generation studies planned for H1 2025.
The company's VELDONA low-dose interferon therapy is advancing with clinical trials for Sjögren's Syndrome and HIV-related oral warts scheduled to begin in H1 2025. A strategic partnership with Taiwan Tanabe Seiyaku Co. will support VELDONA's manufacturing and commercialization. The company also plans to complete veterinary trials for feline chronic gingivostomatitis by H1 2025.
Ainos (NASDAQ:AIMD) outlines its achievements and future plans in AI-powered healthcare technology. The company is developing Smell ID, an AI-powered smell detection technology, and advancing VELDONA®, a low-dose interferon therapeutic. Key developments include:
- The Ainos Flora device for STI testing achieved 94% accuracy in clinical trials, with second-generation studies planned for H1 2025
- VOC detection platform reached 80% accuracy through collaborations with Nisshinbo Micro Devices and Itochu Techno-Solutions
- Clinical trials for VELDONA® targeting Sjögren's Syndrome and HIV-related oral warts are set to begin in H1 2025
- Strategic partnership with Taiwan Tanabe Seiyaku for VELDONA® manufacturing and commercialization
Ainos (NASDAQ:AIMD), a healthcare company specializing in AI-driven point-of-care testing and low-dose interferon therapeutics, has announced its participation in the Webull Corporate Connect Service (CCS). This strategic move aims to enhance investor engagement and transparency through real-time communication with shareholders.
Through the CCS platform, Ainos will showcase corporate milestones, strategic initiatives, and financial results to the investment community. The company's Chairman and CEO, Chun-Hsien Tsai, emphasized that this integration aligns with their commitment to transparent investor communication and will help drive long-term shareholder value.
Ainos (NASDAQ:AIMD) has formed a strategic partnership with Taiwan Tanabe Seiyaku, a Mitsubishi Tanabe Pharma subsidiary, for manufacturing and marketing VELDONA® in Taiwan. The partnership focuses on advancing VELDONA®, a therapeutic candidate for primary Sjögren's syndrome.
The collaboration leverages Taiwan Tanabe Seiyaku's PIC/S GMP-certified facility and expertise in drug manufacturing and market promotion. A clinical study of VELDONA® has received Institutional Review Board approval from Shuang Ho Hospital, with site initiation planned for April 2025 and completion expected in December 2026. Previous U.S. Phase 3 studies showed VELDONA® benefits in improving oral dryness and salivary function for Sjögren's syndrome, an autoimmune disease affecting 0.1-1.0% of the global population.
Ainos (NASDAQ: AIMD) has signed a strategic Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku, a subsidiary of Mitsubishi Tanabe Pharma , to advance the manufacturing and Taiwan market promotion of VELDONA®, their Sjögren's syndrome treatment drug. The partnership leverages Taiwan Tanabe Seiyaku's pharmaceutical development and manufacturing expertise. VELDONA®, a low-dose oral interferon-alpha, has shown promising results in clinical trials, demonstrating significant symptom alleviation and disease progression control. The collaboration aims to accelerate VELDONA®'s global market introduction, targeting the growing Sjögren's syndrome market projected to reach billions in the next five years.
Water Tower Research has published a report highlighting Ainos (NASDAQ:AIMD) receiving IRB approval from Shuang Ho Hospital for its VELDONA clinical study in primary Sjogren's syndrome. The trial is expected to begin around April 2025 after TFDA approval, with completion targeted for December 2026. The study will enroll 24 patients over 24-48 weeks to evaluate VELDONA's efficacy in improving salivary flow. Previous U.S. Phase 3 studies showed positive results. The company recently secured exclusive licenses to 28 patent assets for AI Nose VOC sensing, POCT, and other technologies. Ainos maintains sufficient cash to support operations through 2H25.